H. Lundbeck, new pharmaceutical candidate in Lundbeck’s pipeline

Lundbeck has initiated phase I clinical trials with its pharmaceutical candidate Lu AA34893 to investigate the tolerability and pharmacokinetic profile of the compound in humans.